Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (NASDAQ: GNPX) announced promising preclinical findings in a study published in Cancers, demonstrating that its ONCOPREX® Nanoparticle Delivery System effectively restores FAS expression in mouse models of metastatic colorectal cancer. This delivery system showed potential in suppressing tumor growth and increasing survival rates. The company plans to expand its oncology programs, leveraging these results to explore additional therapeutic genes for various cancers. The ONCOPREX system is also pivotal in Genprex's ongoing lung cancer trials.
Genprex, Inc. has announced plans to accelerate the opening of clinical trial sites for the Acclaim-1 trial, which investigates the combination of REQORSA™ and AstraZeneca's Tagrisso® in treating non-small cell lung cancer (NSCLC). Four sites are opening to enroll patients in the Phase 1 portion of the trial, with additional sites anticipated for Phase 2. The trial will evaluate the therapy’s efficacy in patients previously treated with Tagrisso. An interim analysis will be conducted at 25 events, and the Phase 2 primary endpoint is progression-free survival.
Genprex, a clinical-stage gene therapy company (NASDAQ: GNPX), announced its participation in key investor and healthcare conferences in January 2022. CEO Rodney Varner and CMO Mark Berger will lead presentations at events including the HC Wainwright BIOCONNECT, Biotech Showcase, and the Precision Lung Cancer World R&D Summit. The CEO Roadshow presentation is scheduled for January 26, 2022. Genprex focuses on developing gene therapies for cancer and diabetes, utilizing their proprietary ONCOPREX® delivery system. REQORSA™, their lead candidate for lung cancer, has received Fast Track Designation from the FDA.
Genprex, Inc. (NASDAQ: GNPX) has expanded its research pipeline to include small cell lung cancer (SCLC) for its lead drug candidate, REQORSA™. SCLC accounts for 10-15% of the lung cancer market, while non-small cell lung cancer (NSCLC) represents 84%. The Chief Medical Officer noted that REQORSA might be effective due to low TUSC2 protein levels in SCLC. The company aims to address unmet medical needs in cancer treatments, potentially improving patient outcomes significantly.
Genprex, Inc. (NASDAQ: GNPX) announced that the FDA granted a second Fast Track Designation for its lead drug candidate, REQORSA Immunogene Therapy. This designation applies to the drug used in combination with Keytruda for patients with late-stage non-small cell lung cancer (NSCLC). Genprex plans to start the Acclaim-2 clinical trial in early 2022. As of Q3 2021, the Company had a strong cash position of $42 million, positioning it well for clinical development efforts in 2022.
Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will present at the CEO Roadshow on November 17 at 11 a.m. ET. The webinar will focus on Genprex's innovative gene therapies targeting cancer and diabetes. Attendees will have an opportunity for questions post-presentation. The session will be recorded and accessible on Genprex’s website. Genprex specializes in advanced gene therapy solutions, including its lead product REQORSA™, aimed at treating non-small cell lung cancer.
Genprex, Inc. strengthens its leadership team by appointing Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer. These additions come as the company advances its Acclaim-1 and Acclaim-2 clinical trials for REQORSA, a systemic gene therapy targeting non-small cell lung cancer (NSCLC). Both leaders bring extensive experience in oncology and gene therapy, aiming to enhance Genprex's pipeline and clinical strategy. Additionally, they were granted stock options at an exercise price of $2.85.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its President and CEO, Rodney Varner, will present at two upcoming investor conferences in September 2021.
The CEO Roadshow Webinar is scheduled for September 22, 2021, at 11:00 a.m. ET, while the Benzinga Healthcare Small Cap Conference takes place on September 29, 2021, at 1:15 p.m. ET.
These presentations will demonstrate Genprex's innovative therapies for cancer and diabetes and will be available for replay on their website.
Genprex, Inc. (NASDAQ: GNPX) has announced that its President and CEO, Rodney Varner, will participate in a webinar series with CEO Roadshow to present a company overview to investors each month from July to September 2021. Key dates include July 21, August 18, and September 22. The webinars will include a Q&A session and will be available for replay. Genprex focuses on developing gene therapies for cancer and diabetes, with its lead product, REQORSA™, undergoing evaluation for non-small cell lung cancer.
Genprex, Inc. (GNPX) announced FDA confirmation that all comments regarding its Acclaim-1 clinical trial protocol have been addressed. This Phase 1/2 trial evaluates REQORSA™ Immunogene Therapy combined with AstraZeneca's Tagrisso® for late-stage non-small cell lung cancer patients who have progressed after Tagrisso treatment. Genprex has engaged its first clinical site and aims to enroll 18 patients in Phase 1 and 74 in Phase 2. The trial’s primary endpoint is progression-free survival, with an interim analysis planned at 51 events.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
